Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
At AstraZeneca, our Gastrointestinal (GI) Oncology team has a bold ambition: to eliminate GI cancers as a cause of death.
The rising incidence of GI cancers underscores the need to improve patient outcomes, with a particular unmet need in earlier stages where the potential to extend survival is greatest.
AstraZeneca are committed to advancing our scientific understanding and pushing the boundaries of science to deliver new approaches that can drive meaningful change for patients and their loved ones, harnessing our breadth of scientific platforms to target GI cancers from multiple angles.
By partnering across the entire cancer ecosystem, we aim to shape a future where every patient can access the high-quality care. Together, we strive to drive early diagnosis, optimise pathways across the NHS, better utilise targeted medicines and address health inequalities to redefine what it means to live with GI cancers today and in the future. We invite you to learn more about our initiatives and join our GI oncology revolution.
GB-77235 | June 2026
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
GB-74216| DOP : February 2026
